US+1 646-781-8004
Europe+44-203-868-8738
APAC+91-744-778-0008
sales@meticulousresearch.com
Home Report
Store
In Vitro Diagnostics Market
In-vitro Diagnostics Market (IVD Market) by Product & Solution (Consumables, Systems, Software & Services), Technology (ELISA, Rapid Tests, PCR, Microbiology), Application (Infectious Diseases, Oncology), End User (Hospitals, Diagnostic Laboratories) – Forecast to 2027
Report ID:MRHC - 104132 Pages: 285 Mar-2021 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursThe In Vitro Diagnostics Market (IVD Market) is expected to reach $118.50 billion by 2027, at a CAGR of 7% during the forecast period, 2020 to 2027. The increasing global prevalence of acute and chronic infectious diseases associated with the rising geriatric population, growing awareness regarding early disease diagnosis, a shift in the focus from centralized to point-of-care testing, and the emergence of the COVID-19 pandemic are the key factors driving the growth of the IVD market. Besides, emerging economies, the development of condition-specific markers and tests, and advances in genomics and proteomics offer significant growth opportunities for the players operating in this market.
The Impact of COVID-19 on the In-vitro Diagnostics Market
The COVID-19 pandemic has adversely hit many economies around the globe. The pandemic has affected more than 100 countries infecting more than 87,703,109 people, resulting in 1,892,685 deaths as of 7th January 2020 (Source: World Health Organization). As a measure to control the spread of this disease and avoid related severe consequences, governments across the globe have announced partial or complete lockdown, which has majorly impacted many manufacturing and service industries. Although healthcare professionals are working tirelessly on the frontlines to fight against this crisis, it’s equally important to minimize disease spread by preparing kits for early diagnosis. Testing is one of the greatest tools in understanding and managing the coronavirus pandemic. In response to the growing COVID-19 pandemic and shortages of laboratory-based molecular testing capacity and reagents, multiple diagnostic test manufacturers have developed and started selling various assays & kits prepared using IVD reagents. These simple test kits work either by detecting proteins from the COVID-19 virus in respiratory samples (e.g., sputum, throat swab), blood, or serum of human antibodies generated in response to the infection.
Apart from this, organizations worldwide are coming together and innovating to minimize the impact of COVID-19 on public health and limit the disruption of economies and supply chains. For instance, European governments have pledged over $ 7.67 billion (EUR 7 billion) in initial funding as part of a global effort to respond to the COVID-19 pandemic. Global technology leader Cisco Systems, Inc. (U.S.) is investing $ 225 million to help fight the COVID-19 pandemic.
Amidst the pandemic, manufacturers are contributing by developing various diagnostic kits and assays for early disease diagnosis, driving the growth of the IVD market. For instance, in October 2020, Abbott Laboratories (U.S.) received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for its AdviseDx SARS-CoV-2 IgM (Immunoglobulin M) lab-based serology test. Thus, the pandemic has boosted the adoption of IVD products and solutions.
Click here to: Get Free Sample Pages of this Report
Shift in Focus from Centralized Laboratory Testing to Point-of-care (POC) Testing to Propel Market Growth
In the past, testing was conducted almost exclusively in centralized laboratories. Centralized laboratory testing is very important for the optimal and consistent functioning of diagnostic processes. In recent years there is a continuous shift towards point-of-care testing services or decentralized clinical laboratory testing from centralized laboratories primarily due to the cost reduction, convenience to patients and clinicians, reduced waiting time for results, improved quality, and proliferation of point-of-care (POC) testing. POC tests can improve patient management in cases of infectious diseases. The decentralized setup also helps physicians monitor patients being treated for infectious diseases and improve clinical workflows.
The key players are developing various tests and instruments for rapid disease diagnosis. For instance, in October 2020, Siemens Healthineers AG (Germany) launched the CLINITEST Rapid COVID-19 Antigen Test to identify individuals infected with the coronavirus in 15 minutes to avoid the spread of COVID-19.
Thus, the increasing virulence of infectious diseases, growth in the use of companion diagnostics, efforts to reduce the cost of equipment required, and rapid advancements in molecular testing for hospital-acquired infections are the major factors driving the use of decentralized laboratories for testing.
Regulatory Processes for High/Moderate-complexity Tests Likely to Hinder Market Growth
Regulatory approval processes for diagnostic devices and tests are tedious. Regulatory approval includes a review of the clinical data, calibration, manufacturing methods, quality control, risk assessment, and other factors to ensure the devices’ reproducibility and safety. Despite this, the primary regulatory hurdle for molecular diagnostic devices is the complexity. However, many institutions worldwide refuse to perform these tests due to their high complexity in POC settings.
Under the U.S. Clinical Laboratory Improvement Amendments of 1988 (CLIA), to use molecular diagnostic tests at POC settings, categorization into low-complexity tests or CLIA waived, i.e., tests that have a low risk of incorrect results is mandatory. As these tests can be used in home-care settings, they should be highly resistant to contamination and yield readily interpretable results in less time, even if used by patients directly without in-depth training on that particular assay.
Apart from the FDA, other state and accreditation agencies like the Joint Commission on Accreditation of Healthcare Organizations have additional requirements and standards for developing point-of-care molecular tests. JCI also inspects the waived status of tests. For high or moderate-complexity tests, it is mandatory to have quality checks at least at the manufacturers’ frequency. All results must be documented. With QC failures, the documentation must include what was done to rectify the problem. On the other hand, there is no need for proficiency testing for waived tests. Moreover, Dutch regulations follow quality and other technical parameters before approval for high or moderate-complexity tests, and it is mandatory that the implementation of POCT and general quality management of POC testing should be organized in collaboration with a laboratory specialist.
Thus, the strict documentation and quality auditing by regulatory bodies for high or moderate-complexity tests hinder their approval process, thereby helping develop the in-vitro diagnostics market.
Key Findings of the Global IVD Market Study:
The Consumables Segment Expected to Record the Highest CAGR During the Forecast Period
The rising awareness regarding the identification of diseases, frequent use of assays & kits in detecting various chronic diseases, commercial availability of a diverse range of reagents, and low costs are responsible for the segment's fastest growth. Also, increased demand for COVID-19 testing products is likely to boost the growth of the consumables segment in the upcoming years.
The Molecular Diagnostics Segment Expected to Register the Highest CAGR During the Forecast Period
New product launches and recent regulatory approvals, easy access to a wide range of reagents, and the emergence of advanced technologies like qRT-PCR are other factors driving this segment’s growth. Apart from this, the emergence of the coronavirus pandemic in November 2019 has spurred the growth of molecular diagnostic techniques as many manufacturers have launched IVD solutions for the diagnosis of coronavirus based on molecular diagnostic techniques.
The Infectious Diseases Segment Estimated to Dominate the IVD Market in 2020
The largest share of this segment is mainly attributed to the rise in the global prevalence of infectious diseases, rising susceptibility of the senior population, focus on the early detection of diseases using specific diagnostic tests, government efforts to improve the accessibility of diagnostic services for infectious diseases, and the emergence of the coronavirus pandemic in November 2019.
The Diagnostic Reference Laboratories Segment Estimated to Account for the Largest Market Share in 2020
Factors contributing to this segment's large share include increasing health expenditures, improvements in the diagnostic-platform technologies used in diagnostic laboratories, and an increasing number of skilled professionals. Additionally, due to the emergence of the COVID-19 pandemic, there has been an exponential rise in patient volumes leading to increased testing in laboratories, which is expected to propel the growth of this segment in the upcoming years.
Asia-Pacific: The Fastest-growing Market
In 2020, North America was estimated to account for the largest share of the IVD market, while Asia-Pacific is expected to register the highest CAGR during the forecast period. The factors driving the growth of the IVD market in Asia-Pacific are the increasing investments by healthcare providers in improving diagnostics infrastructure, the rising need to manage the growing burden of infectious diseases, growing access to healthcare services & advanced products, and an increasing number of hospitals and clinics. The other key factors supporting market growth in the region are the increasing market penetration of health insurance, the rising aging population, and efforts to improve access to diagnostic services.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key players’ product portfolios and geographic presence and key strategies adopted by leading market players in the industry over the past four years. Key players in the IVD market are Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux S.A. (France), Thermo Fisher Scientific (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), DiaSorin S.p.A. (Italy), Ortho Clinical Diagnostics (U.S.), Siemens Healthcare GmbH (Germany), Sysmex Corporation (Japan), and Qiagen N.V. (Netherlands), among others.
Scope of the Report:
In-vitro Diagnostics Market, by Product & Solution
- Consumables
- Systems
- Software & Services
In-vitro Diagnostics Market, by Technology
- Immunoassay/ Immunochemistry
- Enzyme-linked Immunosorbent Assay (ELISA)
- Radioimmunoassay
- Rapid Tests
- Western Blotting
- Enzyme-linked Immunospot Assays
- Biochemistry/Clinical Chemistry
- Molecular Diagnostics
- Polymerase Chain Reaction (PCR)
- Isothermal Nucleic Acid Amplification Technology
- Microarray
- Hybridization
- DNA Sequencing & Next-generation Sequencing
- Microbiology
- Hematology
- Coagulation/Hemostasis
- Urinalysis
- Other Technologies*
(*Other Technologies Include Anatomical Pathology, Histochemistry, and Others.)
In-vitro Diagnostics Market, by Application
- Infectious Diseases
- Oncology
- Endocrinology
- Diabetes
- Cardiology
- Nephrology
- Other Applications*
(*Other Applications Comprise Genetic and Neurological Disorders, Autoimmune Disorders, Hepatology, and Congenital Disorders.)
In-vitro Diagnostics Market, by End User
- Diagnostic Reference Laboratories
- Hospitals & Clinics
- Home Healthcare
- Other End Users*
(*Other End users Comprise Nursing Homes, Academic and Research Institutes, and Transfusion Laboratories.)
In-vitro Diagnostics Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Key Questions Answered in the Report:
The IVD market study covers the market sizes and forecasts for IVD consumables like kits and reagents, IVD instruments and systems, and software & services. The IVD market study in this report includes the value analysis of various segments and subsegments of the in-vitro diagnostics market at the regional and country levels.
The IVD market is projected to reach $118.50 billion by 2027, at a CAGR of 7.0% during the forecast period.
Based on product & solution, the consumables segment is estimated to account for the largest share of the IVD market in 2020.
Based on technology, the immunoassay segment is projected to create more traction owing to the advantages offered by immunoassays, such as their inherent specificity, high-throughput, and low cost. Further, the increasing use of immunoassays in POC & infectious disease testing, the development of novel tests, and the rising demand for immunoassay-based tests are other factors expected to drive this segment's growth.
The rising prevalence of acute & chronic infectious diseases, growing awareness regarding the importance of early disease diagnosis, a shift in the focus from centralized to point-of-care testing, and the emergence of the COVID-19 pandemic are factors propelling the growth of the IVD market. Further, emerging economies, the development of condition-specific markers and tests, and advances in genomics and proteomics offer significant growth opportunities for the players operating in this market.
Emerging countries from Asia and Latin America are projected to offer significant growth opportunities for the vendors operating in this market due to rapid urbanization, increasing investments by healthcare providers towards infrastructure improvement, growing incidence of infectious diseases, and increasing access to healthcare services & advanced products.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Introduction
4.2. Drivers
4.2.1. Rising Prevalence of Acute and Chronic Infectious Diseases
4.2.2. Increase in Funding for Research Activities
4.2.3. Growing Awareness for Early Disease Diagnosis
4.2.4. Shift in the Focus from Centralized to Point-of-Care Testing
4.2.5. The Impact of COVID-19
4.3. Restraints
4.3.1. Technical Requirements and Regulatory Process for High or Moderate-Complexity Tests
4.4. Opportunities
4.4.1. Development of Condition-Specific Markers and Tests
4.4.2. Significant Opportunities in Emerging Markets
4.4.3. Advances in Genomics and Proteomics
4.5. Challenges
4.5.1. Unfavorable Reimbursement Scenario
4.5.2. Lack of Awareness of Specific Symptoms and Diagnosis of Emerging Infections
5. Global In-vitro Diagnostics Market, by Product & Solution
5.1. Introduction
5.2. Consumables
5.3. Systems
5.4. Software & Services
6. Global In-vitro Diagnostics Market, by Technology
6.1. Introduction
6.2. Immunoassay/Immunochemistry
6.2.1 Enzyme-Linked Immunosorbent Assays (ELISA)
6.2.2 Radioimmunoassays
6.2.3. Rapid Tests
6.2.4. Western Blotting
6.2.5. Enzyme-Linked Immunospot Assays
6.3. Biochemistry/Clinical Chemistry
6.4. Molecular Diagnostics
6.4.1. Polymerase Chain Reaction (PCR)
6.4.2. Isothermal Nucleic Acid Amplification Technology
6.4.3. Microarray
6.4.4. Hybridization
6.4.5. DNA Sequencing & Next-generation Sequencing
6.5. Microbiology
6.6. Hematology
6.7. Coagulation/Hemostasis
6.8. Urinalysis
6.9. Other Technologies
7. Global In-vitro Diagnostics Market, by Application
7.1. Infectious Diseases
7.2. Oncology
7.3. Endocrinology
7.4. Diabetes
7.5. Cardiology
7.6. Nephrology
7.7. Other Applications
8. Global In-vitro Diagnostics Market, by End User
8.1. Diagnostic Reference Laboratories
8.2. Hospitals & Clinics
8.3. Home Healthcare
8.4. Other End Users
9. Global In-vitro Diagnostics Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. China
9.4.2. India
9.4.3. Japan
9.4.4. Rest of Asia-Pacific
9.5. Latin America
9.6. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis (2019)
11. Company Profiles
11.1. Becton, Dickinson and Company
11.1.1 Business Overview
11.1.2. Financial Overview
11.1.3. Product Portfolio
11.1.4. Strategic Developments
11.2. Danaher Corporation
11.2.1 Business Overview
11.2.2. Financial Overview
11.2.3. Product Portfolio
11.2.4. Strategic Developments
11.3. Thermo Fisher Scientific Inc.
11.3.1 Business Overview
11.3.2. Financial Overview
11.3.3. Product Portfolio
11.3.4. Strategic Developments
11.4. Abbott Laboratories
11.4.1 Business Overview
11.4.2. Financial Overview
11.4.3. Product Portfolio
11.4.4. Strategic Developments
11.5. Ortho Clinical Diagnostics
11.5.1 Business Overview
11.5.2. Product Portfolio
11.5.3. Strategic Developments
11.6. Siemens Healthcare Gmbh
11.6.1 Business Overview
11.6.2. Financial Overview
11.6.3. Product Portfolio
11.6.4. Strategic Developments
11.7. Sysmex Corporation
11.7.1 Business Overview
11.7.2. Financial Overview
11.7.3. Product Portfolio
11.7.4. Strategic Developments
11.8. Bio-Rad Laboratories, Inc.
11.8.1. Business Overview
11.8.2. Financial Overview
11.8.3. Product Portfolio
11.8.4. Strategic Developments
11.9. biomérieux SA
11.9.1. Business Overview
11.9.2. Financial Overview
11.9.3. Product Portfolio
11.9.4. Strategic Developments
11.10. Diasorin S.P.A.
11.10.1. Business Overview
11.10.2. Financial Overview
11.10.3. Product Portfolio
11.10.4. Strategic Developments
11.11. QIAGEN N.V.
11.11.1 Business Overview
11.11.2. Financial Overview
11.11.3. Product Portfolio
11.11.4. Strategic Developments
11.12. Agilent Technologies, Inc.
11.12.1 Business Overview
11.12.2. Financial Overview
11.12.3. Product Portfolio
11.12.4. Strategic Developments
11.13. F. Hoffmann-La Roche Ltd.
11.13.1. Business Overview
11.13.2. Financial Overview
11.13.3. Product Portfolio
11.13.4. Strategic Developments
12. Appendix
12.1. Questionnaire
12.2. Available Customization
List of Tables
Table 1 Global IVD Market Drivers: Impact Analysis (2020–2027)
Table 2 Global IVD Market Restraints: Impact Analysis (2020–2027)
Table 3 Global In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 4 Global IVD Consumables Market Size, by Country/Region, 2018–2027 (USD Million)
Table 5 Global IVD Systems Market Size, by Country/Region, 2018–2027 (USD Million)
Table 6 Global IVD Software & Services Market Size, by Country/Region, 2018–2027 (USD Million)
Table 7 Global In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 8 Global Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 9 Global Immunoassays Market Size, by Country/Region, 2018–2027 (USD Million)
Table 10 Global Enzyme-Linked Immunosorbent Assays Market Size, by Country/Region, 2018–2027 (USD Million)
Table 11 Global Radioimmunoassays Market Size, by Country/Region, 2018–2027 (USD Million)
Table 12 Global Rapid Tests Market Size, by Country/Region, 2018–2027 (USD Million)
Table 13 Global Western Blotting Market Size, by Country/Region, 2018–2027 (USD Million)
Table 14 Global Enzyme-linked Immunospot Assays Market Size, by Country/Region, 2018–2027 (USD Million)
Table 15 Global Clinical Chemistry Market Size, by Country/Region, 2018–2027 (USD Million)
Table 16 Global Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 17 Global Polymerase Chain Reaction Market Size, by Country/Region, 2018–2027 (USD Million)
Table 18 Global Isothermal Nucleic Acid Amplification Technology Market Size, by Country/Region, 2018–2027 (USD Million)
Table 19 Global Microarray Market Size, by Country/Region, 2018–2027 (USD Million)
Table 20 Global Hybridization Market Size, by Country/Region, 2018–2027 (USD Million)
Table 21 Global DNA Sequencing & Next-generation Sequencing Market Size, by Country/Region, 2018–2027 (USD Million)
Table 22 Global Microbiology Market Size, by Country/Region, 2018–2027 (USD Million)
Table 23 Global Hematology Market Size, by Country/Region, 2018–2027 (USD Million)
Table 24 Global Coagulation and Hemostasis Market Size, by Country/Region, 2018–2027 (USD Million)
Table 25 Global Urinalysis Market Size, by Country/Region, 2018–2027 (USD Million)
Table 26 Global Other IVD Technologies Market Size, by Country/Region, 2018–2027 (USD Million)
Table 27 Global IVD Market Size for Infectious Diseases, by Country/Region, 2018–2027 (USD Million)
Table 28 Global IVD Market Size for Oncology, by Country/Region, 2018–2027 (USD Million)
Table 29 Global IVD Market Size for Endocrinology, by Country/Region, 2018–2027 (USD Million)
Table 30 Global IVD Market Size for Diabetes, by Country/Region, 2018–2027 (USD Million)
Table 31 Global IVD Market Size for Cardiology, by Country/Region, 2018–2027 (USD Million)
Table 32 Global IVD Market Size for Nephrology, by Country/Region, 2018–2027 (USD Million)
Table 33 Global IVD Market Size for Other Applications, by Country/Region, 2018–2027 (USD Million)
Table 34 Global IVD Market Size for Hospitals & Clinics, by Country/Region, 2018–2027 (USD Million)
Table 35 Global IVD Market Size for Diagnostic Reference Laboratories, by Country/Region, 2018–2027 (USD Million)
Table 36 Global IVD Market Size for Home Healthcare, by Country/Region, 2018–2027 (USD Million)
Table 37 Global IVD Market Size for Other End Users, by Country/Region, 2018–2027 (USD Million)
Table 38 Global In-vitro Diagnostics Market Size, by Country/Region, 2018–2027 (USD Million)
Table 39 North America: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 40 North America: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 41 North America: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 42 North America: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 43 North America: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 44 North America: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 45 North America: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 46 U.S.: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 47 U.S.: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 48 U.S.: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 49 U.S.: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 50 U.S.: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 51 U.S.: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 52 Canada: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 53 Canada: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 54 Canada: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 55 Canada: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 56 Canada: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 57 Canada: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 58 Europe: In-vitro Diagnostics Market Size, by Country, 2018–2027 (USD Million)
Table 59 Europe: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 60 Europe: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 61 Europe: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 62 Europe: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 63 Europe: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 64 Europe: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 65 Germany: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 66 Germany: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 67 Germany: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 68 Germany: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 69 Germany: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 70 Germany: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 71 U.K.: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 72 U.K.: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 73 U.K.: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 74 U.K.: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 75 U.K.: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 76 U.K.: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 77 France: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 78 France: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 79 France: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 80 France: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 81 France: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 82 France: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 83 Italy: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 84 Italy: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 85 Italy: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 86 Italy: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 87 Italy: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 88 Italy: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 89 Spain: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 90 Spain: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 91 Spain: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 92 Spain: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 93 Spain: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 94 Spain: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 95 RoE: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 96 RoE: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 97 RoE: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 98 RoE: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 99 RoE: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 100 RoE: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 101 Asia-Pacific: In-vitro Diagnostics Market Size, by Country, 2018–2027 (USD Million)
Table 102 Asia-Pacific: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 103 Asia-Pacific: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 104 Asia-Pacific: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 105 Asia-Pacific: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 106 Asia-Pacific: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 107 Asia-Pacific: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 108 China: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 109 China: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 110 China: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 111 China: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 112 China: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 113 China: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 114 Japan: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 115 Japan: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 116 Japan: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 117 Japan: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 118 Japan: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 119 Japan: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 120 India: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 121 India: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 122 India: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 123 India: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 124 India: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 125 India: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 126 Roapac: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 127 RoAPAC: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 128 RoAPAC: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 129 RoAPAC: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 130 RoAPAC: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 131 RoAPAC: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 132 Latin America: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 (USD Million)
Table 133 Latin America: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 134 Latin America: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 135 Latin America: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 136 Latin America: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 137 Latin America: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 138 Middle East & Africa: In-vitro Diagnostics Market Size, by Product & Solution, 2018–2027 ( USD Million)
Table 139 Middle East & Africa: In-vitro Diagnostics Market Size, by Technology, 2018–2027 (USD Million)
Table 140 Middle East & Africa: Immunoassays Market Size, by Type, 2018–2027 (USD Million)
Table 141 Middle East & Africa: Molecular Diagnostics Market Size, by Type, 2018–2027 (USD Million)
Table 142 Middle East & Africa: In-vitro Diagnostics Market Size, by Application, 2018–2027 (USD Million)
Table 143 Middle East & Africa: In-vitro Diagnostics Market Size, by End User, 2018–2027 (USD Million)
Table 144 Recent Developments, by Company, 2017–2020
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Methodology
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Size Estimation
Figure 7 Global In-vitro Diagnostics Market Size, by Product & Solution, 2020 Vs. 2027 (USD Million)
Figure 8 Global In-vitro Diagnostics Market Size, by Technology, 2020 Vs. 2027 (USD Million)
Figure 9 Global In-vitro Diagnostics Market Size, by Application, 2020 Vs. 2027 (USD Million)
Figure 10 Hospital & Clinics Are Expected to Dominate the IVD Market, by End User (2020–2027)
Figure 11 IVD Market Size, by Region
Figure 12 Market Dynamics
Figure 13 Global In-vitro Diagnostics Market Size, by Product & Solution, 2020–2027 (USD Million)
Figure 14 Global In-vitro Diagnostics Market Size, by Technology, 2020–2027 (USD Million)
Figure 15 Global In-vitro Diagnostics Market Size, by Application, 2020–2027 (USD Million)
Figure 16 Global In-vitro Diagnostics Market Size, by End User, 2020–2027 (USD Million)
Figure 17 Global In-vitro Diagnostics Market Size, by Geography, 2020–2027 (USD Million)
Figure 18 North America: In-vitro Diagnostics Market Snapshot
Figure 19 Europe: In-vitro Diagnostics Market Snapshot
Figure 20 Asia-Pacific: In-vitro Diagnostics Market Snapshot
Figure 21 Key Growth Strategies Adopted by Leading Players, 2017–2020
Figure 22 Global In-vitro Diagnostics Market: Competitive Benchmarking
Figure 23 Market Share Analysis: IVD Industry, 2019
COVID-19
This report provides pre & post COVID-19 market estimates.
Related Reports
Indonesia In Vitro Diagnostics Market - Opportunity Analysis And Industry Forecast (2022-2029)
Published Date: Sep-2022
Nepal In Vitro Diagnostics Market - Opportunity Analysis And Industry Forecast (2022-2029)
Published Date: Sep-2022
Tissue Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2022-2029)
Published Date: Sep-2022
HLA Typing Market - Global Opportunity Analysis And Industry Forecast (2022-2029)
Published Date: Jun-2022
